TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from Medtide, Inc. Class H ( (HK:3880) ) is now available.
Medtide Inc. has reported strong financial performance for the first half of 2025, with a 28.5% increase in revenue and a 101.7% rise in profit compared to the previous year. The company has successfully completed a Global Offering and became a listed company in June 2025. Medtide is actively expanding its facilities and workforce to meet the growing global demand for Tides CRDMO services, while continuing to secure new projects and maintain high utilization rates for its production lines. The company’s strategic growth and recent achievements, including ISO certification and marketing approval for Goserelin Acetate APIs in China, position it well for further expansion in the peptide drug industry.
The most recent analyst rating on (HK:3880) stock is a Hold with a HK$38.00 price target. To see the full list of analyst forecasts on Medtide, Inc. Class H stock, see the HK:3880 Stock Forecast page.
More about Medtide, Inc. Class H
Medtide Inc. is a significant player in the global peptide drug industry, offering world-class integrated CRDMO services for peptides and oligonucleotides. The company focuses on providing full-cycle solutions from drug discovery to commercial manufacturing, with a service footprint in over 50 countries. Medtide is expanding its presence in the GLP-1 peptide segment within the Tides drug market.
Average Trading Volume: 610,504
For an in-depth examination of 3880 stock, go to TipRanks’ Overview page.